Sebastian Stintzing

List of Publications by Citations

221 papers	5,709 citations	35 h-index	71 g-index
305 ext. papers	7,019 ext. citations	4.7 avg, IF	5.67 L-index

#	Paper	IF	Citations
221	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. *Lancet Oncology, The*, **2014**, 15, 1065-75	21.7	1169
220	Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. *JAMA Oncology*, **2017**, 3, 194-201	13.4	409
219	The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. *European Journal of Cancer*, **2017**, 70, 87-98	7.5	311
218	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. *Lancet Oncology, The*, **2016**, 17, 1426-1434	21.7	246
217	Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. *Cancer Treatment Reviews*, **2009**, 35, 262-71	14.4	157
216	Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. *European Journal of Cancer*, **2017**, 84, 69-80	7.5	136
215	Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. *Annals of Oncology*, **2016**, 27, 1746-53	10.3	127
214	Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). *European Journal of Cancer*, **2015**, 51, 1927-36	7.5	113
213	Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. *Journal of Clinical Oncology*, **2011**, 29, 1050-8	2.2	92
212	Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. *Journal of Cancer Research and Clinical Oncology*, **2014**, 140, 1607-14	4.9	90
211	Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer. *Journal of Clinical Oncology*, **2015**, 33, 3718-26	2.2	89
210	TAS-102, a novel antitumor agent: a review of the mechanism of action. *Cancer Treatment Reviews*, **2015**, 41, 777-83	14.4	80
209	The Treatment of Colorectal Carcinoma With Monoclonal Antibodies: In reply. *Deutsches Ärzteblatt International*,	2.5	78
208	Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. *Annals of Oncology*, **2019**, 30, 1796-1803	10.3	77
207	Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. *European Journal of Cancer*, **2017**, 79, 50-60	7.5	75
206	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. *Annals of Oncology*, **2012**, 23, 1693-9	10.3	70
205	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. *Journal of the National Cancer Institute*, **2019**, 111, 146-157	9.7	67

204	Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. *Frontiers in Oncology*, **2019**, 9, 849	5.3	67
203	NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. *International Journal of Cancer*, **2015**, 137, 678-85	7.5	63
202	Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. *International Journal of Cancer*, **2013**, 132, 236-45	7.5	59
201	Management of colorectal cancer. *F1000prime Reports*, **2014**, 6, 108		57
200	Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials. *Clinical Cancer Research*, **2013**, 19, 225-35	12.9	51
199	Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3 A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.. *Journal of Clinical Oncology*, **2014**, 32, 445-445	2.2	48
198	Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial. *Acta Oncologica*, **2013**, 52, 956-62	3.2	47
197	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019**, 10, 431	17.4	45
196	Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial. *Cancer Science*, **2013**, 104, 718-24	6.9	45
195	Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).. *Journal of Clinical Oncology*, **2013**, 31, LBA3506-LBA3506	2.2	43
194	A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. *European Journal of Cancer*, **2016**, 67, 11-20	7.5	40
193	CT fluoroscopy-guided percutaneous fiducial marker placement for CyberKnife stereotactic radiosurgery: technical results and complications in 222 consecutive procedures. *Journal of Vascular and Interventional Radiology*, **2014**, 25, 760-8	2.4	39
192	Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment). *Anti-Cancer Drugs*, **2014**, 25, 212-8	2.4	38
191	Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. *Anti-Cancer Drugs*, **2011**, 22, 913-8	2.4	38
190	Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases. *Acta Oncologica*, **2013**, 52, 971-7	3.2	37
189	The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial. *International Journal of Cancer*, **2012**, 131, 980-6	7.5	37
188	Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. *World Journal of Gastroenterology*, **2019**, 25, 3136-3150	5.6	37
187	The expression pattern of PDX-1, SHH, Patched and Gli-1 is associated with pathological and clinical features in human pancreatic cancer. *Pancreatology*, **2009**, 9, 116-26	3.8	35

186	Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306). *Oncotarget*, **2017**, 8, 105749-105760	3.3	35
185	Independent Radiological Evaluation of Objective Response, Early Tumor Shrinkage, and Depth of Response in Fire-3 (Aio Krk-0306) in the Final Ras Evaluable Population. *Annals of Oncology*, **2014**, 25, v1	10.3	34
184	Detection of Chlamydia pneumoniae but not of Helicobacter pylori in symptomatic atherosclerotic carotids associated with enhanced serum antibodies, inflammation and apoptosis rate. *Atherosclerosis*, **2003**, 168, 153-62	3.1	34
183	Overexpression of MMP9 and tissue factor in unstable carotid plaques associated with Chlamydia pneumoniae, inflammation, and apoptosis. *Annals of Vascular Surgery*, **2005**, 19, 310-9	1.7	33
182	Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer. *British Journal of Cancer*, **2012**, 107, 1678-83	8.7	31
181	ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer. *ESMO Open*, **2020**, 5,	6	31
180	Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies. *Lancet Oncology, The*, **2019**, 20, e274-e283	21.7	30
179	Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.. *Journal of Clinical Oncology*, **2017**, 35, 3510-3510	2.2	30
178	Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. *ESMO Open*, **2018**, 3, e000353	6	30
177	Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in Wild-Type Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2019**, 25, 134-141	12.9	28
176	Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy. *Molecular Cancer Therapeutics*, **2014**, 13, 528-39	6.1	27
175	Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives. *Visceral Medicine*, **2016**, 32, 178-83	2.4	25
174	Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial). *International Journal of Cancer*, **2016**, 138, 739-46	7.5	25
173	Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110). *Journal of Clinical Oncology*, **2019**, 37, 22-32	2.2	24
172	Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work. *Hematology/Oncology Clinics of North America*, **2015**, 29, 43-60	3.1	24
171	Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. *Pharmacogenomics Journal*, **2015**, 15, 69-76	3.5	24
170	Resection of pulmonary metastases from colon and rectal cancer: factors to predict survival differ regarding to the origin of the primary tumor. *Annals of Surgical Oncology*, **2014**, 21, 2563-72	3.1	24
169	Differentiation patterning of vascular smooth muscle cells (VSMC) in atherosclerosis. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2009**, 455, 171-85	5.1	24

168	Radiosurgery of liver tumors: value of robotic radiosurgical device to treat liver tumors. *Annals of Surgical Oncology*, **2010**, 17, 2877-83	3.1	24
167	Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial.. *Journal of Clinical Oncology*, **2014**, 32, 3600-3600	2.2	24
166	Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients. *European Journal of Cancer*, **2010**, 46, 1026-32	7.5	22
165	Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer. *Annals of Oncology*, **2015**, 26, 332-9	10.3	20
164	Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials. *Annals of Oncology*, **2015**, 26, 2450-6	10.3	20
163	Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials. *Oncology*, **2012**, 83, 241-7	3.6	20
162	CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). *Annals of Oncology*, **2016**, 27, 1565-72	10.3	20
161	Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. *Annals of Oncology*, **2017**, 28, 2780-2785	10.3	19
160	Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. *British Journal of Cancer*, **2011**, 105, 206-11	8.7	19
159	Different capabilities of morphological pattern formation and its association with the expression of differentiation markers in a xenograft model of human pancreatic cancer cell lines. *Pancreatology*, **2005**, 5, 387-97	3.8	18
158	FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. *British Journal of Cancer*, **2021**, 124, 587-594	8.7	18
157	Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial. *British Journal of Cancer*, **2013**, 109, 1428-36	8.7	17
156	Independent Radiological Evaluation of Objective Response Early Tumor Shrinkage, and Depth of Response in FIRE-3 (AIO KRK-0306). *Annals of Oncology*, **2014**, 25, ii117	10.3	17
155	Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States. *Molecular Cancer Therapeutics*, **2013**, 12, 2261-72	6.1	17
154	Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. *Clinical Cancer Research*, **2016**, 22, 3218-26	12.9	16
153	Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?. *Journal of Biomedicine and Biotechnology*, **2011**, 2011, 214143		16
152	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. *European Journal of Cancer*, **2017**, 77, 13-20	7.5	15
151	Primary testicular lymphoma: a strictly homogeneous hematological disease?. *Oncology Reports*, **2010**, 23, 1261-7	3.5	15

150	The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status. *Deutsches Ärzteblatt International*, **2009**, 106, 202-6	2.5	15
149	Role of cannabinoid receptors and RAGE in inflammatory bowel disease. *Histology and Histopathology*, **2011**, 26, 735-45	1.4	15
148	Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. *International Journal of Cancer*, **2017**, 141, 1222-1230	7.5	14
147	Surrogate endpoints in second-line treatment for mCRC: a systematic literature-based analysis from 23 randomised trials. *Acta Oncologica*, **2015**, 54, 187-93	3.2	14
146	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. *Clinical Cancer Research*, **2018**, 24, 784-793	12.9	14
145	Combined resection of colorectal hepatic-pulmonary metastases shows improved outcome over chemotherapy alone. *Langenbecks Archives of Surgery*, **2013**, 398, 265-76	3.4	13
144	KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer. *Journal of Cancer Research and Clinical Oncology*, **2013**, 139, 953-61	4.9	13
143	Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib/IIa Study. *Cancers*, **2020**, 12,	6.6	12
142	FOLFIRI with cetuximab or bevacizumab: FIRE-3-authors' reply. *Lancet Oncology, The*, **2014**, 15, e583-e584	31.7	12
141	Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis. *Anti-Cancer Drugs*, **2012**, 23, 666-73	2.4	12
140	Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer. *Pharmacogenomics Journal*, **2016**, 16, 312-9	3.5	11
139	Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer. *Anti-Cancer Drugs*, **2017**, 28, 717-722	2.4	11
138	Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306). *International Journal of Cancer*, **2017**, 140, 1918-1925	7.5	11
137	Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer. *Pharmacogenetics and Genomics*, **2015**, 25, 30-7	1.9	11
136	CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial. *European Radiology*, **2018**, 28, 5284-5292	8	11
135	Molecular pathways: turning proteasomal protein degradation into a unique treatment approach. *Clinical Cancer Research*, **2014**, 20, 3064-70	12.9	11
134	Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancer. *International Journal of Cancer*, **2019**, 144, 569-581	7.5	11
133	Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial. *Frontiers in Oncology*, **2018**, 8, 474	5.3	11

132	The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2018**, 473, 199-207	5.1	10
131	Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels. *Anti-Cancer Drugs*, **2013**, 24, 969-74	2.4	10
130	Recent advances in understanding colorectal cancer. *F1000Research*, **2018**, 7,	3.6	10
129	CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy. *Pharmacogenomics Journal*, **2017**, 17, 543-550	3.5	9
128	Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases. *Cancer*, **2015**, 121, 1898-905	6.4	9
127	Panitumumab safety for treating colorectal cancer. *Expert Opinion on Drug Safety*, **2014**, 13, 843-51	4.1	9
126	Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306). *Annals of Oncology*, **2020**, 31, 72-78	10.3	9
125	Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. *Cancer Treatment Reviews*, **2021**, 97, 102172	14.4	9
124	Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. *Clinical Colorectal Cancer*, **2019**, 18, e8-e19	3.8	9
123	Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). *European Journal of Cancer*, **2019**, 106, 115-125	7.5	9
122	Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib. *Anti-Cancer Drugs*, **2015**, 26, 371-8	2.4	8
121	Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial. *International Journal of Cancer*, **2018**, 142, 1047-1055	7.5	8
120	Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group. *Annals of Oncology*, **2013**, 24, 3051-5	10.3	8
119	Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases. *Pharmacogenomics Journal*, **2015**, 15, 521-9	3.5	8
118	Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients. *Pharmacogenetics and Genomics*, **2014**, 24, 588-96	1.9	8
117	A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial. *BMC Cancer*, **2011**, 11, 367	4.8	8
116	Multidisciplinary treatment of colorectal liver metastases. *Minerva Medica*, **2017**, 108, 527-546	2.2	8
115	Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212). *Journal of Clinical Oncology*, **2021**, JCO2101332	2.2	8

114	Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer. *Pharmacogenomics Journal*, **2017**, 17, 528-534	3.5	7
113	KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer. *Future Oncology*, **2015**, 11, 1919-29	3.6	7
112	Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306. *Annals of Surgical Oncology*, **2020**, 27, 2389-2401	3.1	7
111	Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. *Molecular Cancer Therapeutics*, **2016**, 15, 1740-5	6.1	7
110	Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).. *Journal of Clinical Oncology*, **2021**, 39, 3502-3502	2.2	7
109	Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. *Cancer Treatment Reviews*, **2021**, 98, 102218	14.4	7
108	Genetic variants associated with colorectal brain metastases susceptibility and survival. *Pharmacogenomics Journal*, **2017**, 17, 29-35	3.5	6
107	Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases. *Annals of Oncology*, **2015**, 26, 1728-33	10.3	6
106	Diffusion-weighted MRI Before and After Robotic Radiosurgery (Cyberknife®) in Primary and Secondary Liver Malignancies: A Pilot Study. *Technology in Cancer Research and Treatment*, **2015**, 14, 191-9	2.7	6
105	Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials. *Journal of Cancer Research and Clinical Oncology*, **2020**, 146, 2077-2087	4.9	6
104	Synchronous colorectal liver metastases: focus on the elderly : An Effectiveness Study from Routine Care. *Langenbecks Archives of Surgery*, **2017**, 402, 1223-1232	3.4	6
103	Under-expression of β8 integrin aggravates experimental atherosclerosis. *Journal of Pathology*, **2015**, 236, 5-16	9.4	6
102	Amphiregulin Expression Is a Predictive Biomarker for Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials. *Clinical Cancer Research*, **2020**, 26, 6559-6567	12.9	6
101	Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. *International Journal of Cancer*, **2017**, 141, 383-392	7.5	5
100	Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104. *Acta Oncologica*, **2015**, 54, 993-1000	3.2	5
99	Towards volumetric thresholds in RECIST 1.1: Therapeutic response assessment in hepatic metastases. *European Radiology*, **2018**, 28, 4839-4848	8	5
98	Study evidence confirms current clinical practice in refractory metastatic colorectal cancer: the ReDOS trial. *Lancet Oncology, The*, **2019**, 20, 1036-1037	21.7	5
97	Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial. *European Journal of Cancer*, **2020**, 137, 250-259	7.5	5

96	Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. *European Journal of Cancer*, **2019**, 107, 100-114	7.5	5
95	Evaluation for surgical treatment options in metastatic colorectal cancer (mCRC) a retrospective, central evaluation of FIRE-3. *Annals of Oncology*, **2016**, 27, vi154	10.3	4
94	Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer. *Cancer Treatment Reviews*, **2016**, 45, 97-104	14.4	4
93	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. *Pharmacogenomics Journal*, **2018**, 18, 623-632	3.5	4
92	Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!. *Expert Opinion on Pharmacotherapy*, **2013**, 14, 2203-20	4	4
91	Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer. *Clinical Colorectal Cancer*, **2011**, 10, 317-24	3.8	4
90	Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. *Frontiers in Oncology*, **2021**, 11, 670396	5.3	4
89	Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. *European Journal of Cancer*, **2019**, 111, 138-147	7.5	3
88	Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. *Molecular Cancer Therapeutics*, **2015**, 14, 2374-81	6.1	3
87	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. *European Journal of Cancer*, **2020**, 131, 89-97	7.5	3
86	NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. *PLoS ONE*, **2018**, 13, e0193640	3.7	3
85	Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study. *Clinical Colorectal Cancer*, **2018**, 17, 215-222.e3	3.8	3
84	Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306). *European Journal of Cancer*, **2017**, 84, 262-269	7.5	3
83	FIRE-4.5-Studie **2017**, 32, 54-56	0.2	3
82	Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109). *Journal of Cancer Research and Clinical Oncology*, **2020**, 146, 2681-2691	4.9	3
81	Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study. *Journal of Medical Economics*, **2020**, 23, 448-455	2.4	3
80	Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology Association. *ESMO Open*, **2020**, 5, e001001	6	3
79	The DNA-polymorphism rs849142 is associated with skin toxicity induced by targeted anti-EGFR therapy using cetuximab. *Oncotarget*, **2018**, 9, 30279-30288	3.3	3

78	Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models. *Genome Medicine*, **2021**, 13, 116	14.4	3
77	Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer. *Oncologist*, **2021**, 26, e2110-e2114	5.7	3
76	Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial. *European Journal of Radiology*, **2018**, 100, 124-129	4.7	2
75	Prognostic impact of FOXF1 polymorphisms in gastric cancer patients. *Pharmacogenomics Journal*, **2018**, 18, 262-269	3.5	2
74	2Nd-Line Therapies After 1St-Line Therapy with Folfiri in Combination with Cetuximab or Bevacizumab in Patients with Kras Wild-Type Metastatic Colorectal Cancer (Mcrc)-Analysis of the Aio Krk 0306 (Fire 3)- Trial. *Annals of Oncology*, **2014**, 25, iv172	10.3	2
73	2ND-Line Therapies After 1st-Line Therapy with Folfiri in Combination with Cetuximab or Bevacizumab in Patients with KRAS Wild-Type Metastatic Colorectal Cancer (MCRC)-Analysis of the AIO KRK 0306 (FIRE 3)- Trial. *Annals of Oncology*, **2014**, 25, ii112	10.3	2
72	Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent. *Pharmacogenetics and Genomics*, **2014**, 24, 539-47	1.9	2
71	Long-term Survival in Patients Treated with a Robotic Radiosurgical Device for Liver Metastases. *Cancer Research and Treatment*, **2019**, 51, 187-193	5.2	2
70	Frameless Single Robotic Radiosurgery for Pulmonary Metastases in Colorectal Cancer Patients. *Cureus*, **2020**, 12, e7305	1.2	2
69	Maintenance therapy with 5-fluoruracil/leucovorin (5FU/LV) plus panitumumab (pmab) or 5FU/LV alone in RAS wildtype (WT) metastatic colorectal cancer (mCRC) - the PANAMA trial (AIO KRK 0212).. *Journal of Clinical Oncology*, **2021**, 39, 3503-3503	2.2	2
68	Partition: a surjective mapping approach for dimensionality reduction. *Bioinformatics*, **2020**, 36, 676-681	7.2	2
67	Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant Treatment. *Journal of Gastrointestinal Surgery*, **2021**, 25, 58-66	3.3	2
66	Association of microRNA-21 (miR-21) with efficacy of cetuximab (cet) and bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC) within the FIRE-3 study (AIO KRK-0306). *Annals of Oncology*, **2018**, 29, viii39	10.3	2
65	NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?-Case series and review of the literature. *European Journal of Cancer*, **2021**, 153, 86-95	7.5	2
64	Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized PhaseIII trial FIRE-3 (AIO KRK-0306). *International Journal of Cancer*, **2022**, 150, 112-123	7.5	2
63	Efficacy, Molecular Biology, Quality of Life, or Economic Aspects: What Do We Really FOCUS oN?. *Journal of Clinical Oncology*, **2022**, JCO2102310	2.2	2
62	Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306. *Clinical Colorectal Cancer*, **2020**, 19, 291-300.e5	3.8	1
61	Molekulare Stratifizierung von kolorektalen Karzinomen Was hat Relevanz f die klinische Praxis?. *Tumor Diagnostik Und Therapie*, **2018**, 39, 29-32	0.1	1

60	A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. *Pharmacogenomics Journal*, **2018**, 18, 43-48	3.5	1
59	FIRE-6 Studie **2019**, 34, 371-373	0.2	1
58	Sym004: Truly a New Level of Anti-EGFR Treatment?. *Cancer Discovery*, **2015**, 5, 578-80	24.4	1
57	Panitumumab : leading to better overall survival in metastatic colorectal cancer?. *Expert Opinion on Biological Therapy*, **2014**, 14, 535-48	5.4	1
56	Amphiregulin (AREG) SNP rs161511 to predict cetuximab efficacy independent of AREG mRNA levels: Data from FIRE3 (AIO KRK-0306).. *Journal of Clinical Oncology*, **2014**, 32, 3521-3521	2.2	1
55	Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcome of bevacizumab (bev)-based treatment in patients with metastatic colorectal cancer (mCRC): Results from TRIBE and FIRE3 trials.. *Journal of Clinical Oncology*, **2015**, 33, 3552-3552	2.2	1
54	Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line (1L) treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) in Germany: Data from the FIRE-3 (AIO KRK-0306) study.. *Journal of Clinical Oncology*, **2018**, 36, 800-800	2.2	1
53	AGENT: An open-label phase III study of arfolitixorin versus leucovorin in modified FOLFOX-6 for first-line treatment of metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2020**, 38, TPS268-TPS268	2.2	1
52	CyberKnife Radiosurgery - Value as an Adjunct to Surgical Treatment of HCC?. *Cureus*, **2016**, 8, e591	1.2	1
51	Capecitabine (cape)-associated hand-foot skin reaction (HFS) as a clinical predictor of improved survival in patients (pts) with colorectal cancer.. *Journal of Clinical Oncology*, **2012**, 30, 3541-3541	2.2	1
50	Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).. *Journal of Clinical Oncology*, **2013**, 31, LBA3506-LBA3506	2.2	1
49	Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study). *European Journal of Cancer*, **2020**, 137, 81-92	7.5	1
48	Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. *Cancers*, **2021**, 13,	6.6	1
47	Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. *European Journal of Cancer*, **2021**, 150, 133-142	7.5	1
46	A still missing piece of the FIRE-3 puzzle - Authors' reply. *Lancet Oncology, The*, **2016**, 17, e516	21.7	1
45	Importance and Qualitative Requirements of Magnetic Resonance Imaging for Therapy Planning in Rectal Cancer - Interdisciplinary Recommendations of AIO, ARO, ACO and the German Radiological Society. *RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren*,	2.3	1
44	Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3). *International Journal of Cancer*, **2021**, 149, 1935-1943	7.5	1
43	AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. *International Journal of Cancer*, **2019**, 145, 2082-2090	7.5	0

42	Survey of Long-Term Experiences of Sperm Cryopreservation in Oncological and Non-Oncological Patients: Usage and Reproductive Outcomes of a Large Monocentric Cohort. *Frontiers in Oncology*, **2021**, 11, 772809	5.3	0
41	Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials.. *Journal of Clinical Oncology*, **2019**, 37, 3048-3048	2.2	0
40	Variation in genetic polymorphisms and gene expression of HLA-E to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/cetuximab: Data from the phase III FIRE-3 trial.. *Journal of Clinical Oncology*, **2020**, 38, 245-245	2.2	0
39	Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study. *Anti-Cancer Drugs*, **2020**, 31, 856-865	2.4	0
38	RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. *Molecular Cancer Therapeutics*, **2021**, 20, 1153-1160	6.1	0
37	Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110). *European Journal of Cancer*, **2021**, 147, 128-139	7.5	0
36	RAMucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic colorectal cancer: Safety results from the phase IIb part of the RAMTAS phase II/III trial of the German AIO (AIO-KRK-0316).. *Journal of Clinical Oncology*, **2021**, 39, 3566-3566	2.2	0
35	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. *Scientific Reports*, **2021**, 11, 12191	4.9	0
34	Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). *European Journal of Cancer*, **2021**, 157, 71-80	7.5	0
33	Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial.. *Frontiers in Oncology*, **2022**, 12, 751453	5.3	0
32	Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAF-mutant metastatic and/or unresectable colorectal cancer.. *Critical Reviews in Oncology/Hematology*, **2022**, 173, 103646	7	0
31	Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade.. *OncoImmunology*, **2022**, 11, 2068109	7.2	0
30	Antibodies for Treatment of Metastatic Colorectal Cancer **2017**, 217-244		
29	FIRE-5-Studie (AIO TF-0118) **2019**, 34, 367-368	0.2	
28	Therapiesequenz beim metastasierten kolorektalen Karzinom. *InFo H□matologie + Onkologie*, **2020**, 23, 15-21	0	
27	Perioperative Therapie des CRC. *InFo H□matologie + Onkologie*, **2020**, 23, 10-14	0	
26	Forscher und Arzt □ein Widerspruch? **2015**, 30, 335-337	0.2	
25	Wahl der Behandlungsstrategie auf der Basis molekularer Marker. *Im Focus Onkologie*, **2015**, 18, 51-59	0	

24	Predictors of EGF receptor monoclonal antibody activity in metastatic colorectal cancer: current status. *Colorectal Cancer*, **2012**, 1, 423-432	0.8
23	Author's reply to: "Prognostic value of cetuximab related skintoxicity in metastatic colorectal cancer patients and its correlation with parameters of the EGFR signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group". *International Journal of Cancer*, **2013**, 132, 1719-20	7.5
22	The role of germline polymorphisms in genes involved in the antioxidant system to predict the efficacy of cetuximab for patients with metastatic colorectal cancer (mCRC) enrolled in FIRE-3 trial.. *Journal of Clinical Oncology*, **2022**, 40, 143-143	2.2
21	Incidence, severity, and onset of oral mucositis in 5-FU based chemotherapy for gastrointestinal cancer.. *Journal of Clinical Oncology*, **2022**, 40, 77-77	2.2
20	Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.. *Journal of Clinical Oncology*, **2019**, 37, 564-564	2.2
19	Genetic variants in immunogenic cell death (ICD) relating genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE and MAVERICC trials.. *Journal of Clinical Oncology*, **2020**, 38, 187-187	2.2
18	Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status: Analysis of untreated RAS-wildtype mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).. *Journal of Clinical Oncology*, **2020**, 38, e16055-e16055	2.2
17	High amphiregulin mRNA expression is a strong prognostic biomarker with response to cetuximab in FIRE-1, CIOX, and FIRE-3.. *Journal of Clinical Oncology*, **2020**, 38, 4026-4026	2.2
16	AIO KRK0306, FIRE3 trial: CEA and CA19-9 influence outcome of patients with KRAS exon wild-type metastatic colorectal cancer (mCRC) receiving first-line therapy with FOLFIRI plus cetuximab or bevacizumab.. *Journal of Clinical Oncology*, **2014**, 32, 3592-3592	2.2
15	Influence of mRNA expression of epiregulin (EREG) and of amphiregulin (AREG) and RAS mutationson outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).. *Journal of Clinical Oncology*, **2014**, 32, 3522-3522	2.2
14	High-throughput exome array for identification of novel polymorphisms associated with clinical outcome in mCRC patients treated with first-line FOLFOXIRI/BEV versus FOLFIRI/BEV (TRIBE trial; NCT00719797).. *Journal of Clinical Oncology*, **2014**, 32, 3632-3632	2.2
13	Biomarker validation study: Genes involved in ubiquitin proteasome system (UPS) dependent EGFR-degradation for prediction of efficacy in metastatic colorectal cancer patients treated with cetuximab.. *Journal of Clinical Oncology*, **2014**, 32, 3571-3571	2.2
12	Macrophage polarization related gene variants to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with bevacizumab (bev) in combination with FOLFIRI.. *Journal of Clinical Oncology*, **2015**, 33, 621-621	2.2
11	Treatment until progression: Data of the on-treatment population of the FIRE-3 (AIO KRK-0306) study.. *Journal of Clinical Oncology*, **2015**, 33, 3589-3589	2.2
10	Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the AIO KRK 0104 trial.. *Journal of Clinical Oncology*, **2012**, 30, 3588-3588	2.2
9	Course of calcium and magnesium serum levels in cetuximab-treated patients: Relation to concurrent chemotherapy and possible predictive value.. *Journal of Clinical Oncology*, **2013**, 31, 521-521	2.2
8	Palliative Chemo- und Immuntherapie – State of the Art und neue Entwicklungen. *Gastroenterologe*, **2020**, 15, 300-309	0.1
7	FIRE-7-Studie (AIO-KRK-0120) **2021**, 36, 244-246	0.2

6	AIO-FIRE-8-Studie (AIO-KRK/YMO-0519) **2021**, 36, 251-252	0.2
5	The role of PP2A variants to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials.. *Journal of Clinical Oncology*, **2021**, 39, 3581-3581	2.2
4	Treatment responses and disease dynamics in patients with untreated metastatic colorectal cancer receiving bevacizumab-based sequential versus combination chemotherapy: Analysis of a phase 3 trial (AIO KRK0110, XELAVIRI study).. *Journal of Clinical Oncology*, **2021**, 39, 3571-3571	2.2
3	Systemische Therapie des metastasierten Kolonkarzinoms. *Onkologe*, **2021**, 27, 259-266	0.1
2	Genetic variants involved in the lipid metabolism pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC trials.. *Journal of Clinical Oncology*, **2021**, 39, 118-118	2.2
1	FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer.. *BMC Cancer*, **2022**, 22, 359	4.8